41 patents
Utility
Methods of Treating Heart Failure with Cardiac Sarcomere Activators
9 Nov 23
Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
Narimon HONARPOUR, Fady MALIK
Filed: 5 May 23
Utility
Nampt Modulators
2 Nov 23
Antonio ROMERO, Aroop CHANDRA, Christopher EVANS, Minxing SHEN
Filed: 5 May 21
Utility
Methods of Treating Heart Failure with Cardiac Sarcomere Activators
18 May 23
Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
Narimon HONARPOUR, Fady Malik
Filed: 17 Jan 23
Utility
Nampt Modulators
4 May 23
Antonio ROMERO, Aroop CHANDRA, Christopher Edward EVANS, Minxing SHEN
Filed: 5 Feb 21
Utility
Tetrahydroisoquinoline Derivatives
27 Apr 23
Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere.
Ippei SATO, Takashi KAMIKUBO, Masanori MIURA, Yuji MATSUSHIMA, Hiroaki TANAKA, Yasuhiro SHIINA, Susumu YAMAKI, Tomoyuki SAITO, Hiroshi KIYOHARA, Munemichi OHE, Kayoko MIHARA, Bradley Paul MORGAN, Fady MALIK, Scott Emile COLLIBEE, Luke ASHCRAFT, Pu-Ping LU, Jeffrey Michael WARRINGTON, Marc GARARD
Filed: 13 Sep 22
Utility
CD38 Modulators and Methods of Use Thereof
20 Apr 23
Luke W. ASHCRAFT, Chihyuan CHUANG, Alfredo GARCIA, Bradley P. MORGAN, Bartlomiej Przemyslaw IWAN, Molly Eichel MERMIN
Filed: 11 Jul 22
Utility
Cardiac Sarcomere Inhibitors
20 Apr 23
Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
Filed: 31 Aug 22
Utility
Salts and Crystal Forms of Omecamtiv Mecarbil
6 Apr 23
Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Alisa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
Filed: 2 Sep 22
Utility
Cardiac Sarcomere Inhibitors
23 Mar 23
Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Luke W. ASHCRAFT, Kevin LAU
Filed: 4 May 22
Utility
Bicyclic 1,4-DIAZEPANONES and Therapeutic Uses Thereof
16 Mar 23
Bradley P. MORGAN, Chris Evans, Pu-Ping Lu, Makoto Yamasaki, Wenyue Wang, Scott Collibee, Takuya Makino, Kazuyuki Tsuchiya, Toshio Kurosaki, Susumu Yamaki, Eriko Honjo, Yuka Koizumi, Naoto Katoh, Ryuichi Sekioka, Ikumi Kuriwaki, Denise Andersen
Filed: 5 Nov 21
Utility
Methods for Treating Hypertrophic Cardiomyopathy
23 Feb 23
Methods for treating obstructive hypertrophic cardiomyopathy are described herein.
Fady MALIK, Stuart Kupfer, Stephen B. Heitner, Laura Ann Robertson, Lixin Meng, Anna Osmukhina, Qi Wohltman
Filed: 15 Jul 22
Utility
Salt of Omecamtiv Mecarbil and Process for Preparing Salt
9 Feb 23
Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.
Sheng CUI, Henry MORRISON, Karthik NAGAPUDI, Shawn D. WALKER, Charles BERNARD, Karl Bennett HANSEN, Neil Fred LANGILLE, Alan Martin ALLGEIER, Steven MENNEN, Jacqueline C.S. WOO, Bradley Paul MORGAN, Alex MUCI
Filed: 8 Sep 22
Utility
Process for Preparing Aficamten
9 Feb 23
Provided herein is a process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.
Denise ANDERSEN, Matthew PFEIFFER, Norma TOM, Bradley P. MORGAN
Filed: 2 Aug 22
Utility
Amino-pyrimidine Skeletal Muscle Modulators
26 Jan 23
Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
Filed: 20 May 22
Utility
Sulfonamide Compounds As Cardiac Sarcomere Activators
20 Oct 22
The present disclosure relates to sulfonamide compounds and pharmaceutically acceptable salts thereof as cardiac sarcomere activators.
Jeffrey GARDINA, Aroop CHANDRA, Luke W. ASHCRAFT, Scott COLLIBEE, Chihyuan CHUANG, Alex MUCI - DECEASED, Bradley P. MORGAN, Antonio ROMERO, Michael JOHNSON, David MOEBIUS, Hanmo ZHANG, Felix GONZALEZ
Filed: 5 Apr 22
Utility
Polymorphs of 1-(2-((((TRANS)-3-FLUORO-1-(3-FLUOROPYRIDIN-2-YL)CYCLOBUTYL)METHYL)AMINO)PYRIMIDIN-5-YL)-1H-PYRROLE-3-CARBOXAMIDE
6 Oct 22
Bradley P. MORGAN, Matthew W. PETERSON
Filed: 26 Jun 20
Utility
Polymorphs of (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
6 Oct 22
Provided herein are polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, compositions thereof, methods of preparation thereof, and methods of their uses.
Norma TOM, Matthew PFEIFFER, Denise ANDERSEN, Qi GAO
Filed: 16 Jul 20
Utility
Cardiac Sarcomere Inhibitors
29 Sep 22
Bradley P. MORGAN, Chihyuan CHUANG, Luke W. ASHCRAFT, Justin HO, Alfredo GARCIA
Filed: 3 Mar 22
Utility
Heterocyclic Compounds and Their Uses
22 Sep 22
Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
Mingda BI, Robert KUEHL
Filed: 8 Jun 22
Utility
Bisamide Sarcomere Activating Compounds and Uses Thereof
8 Sep 22
Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
Filed: 15 Feb 22